

## ACoP13 Poster Session and Poster ID

<b>Pre-Conference – Sunday, October 30</b>			
<b>Poster ID</b>	<b>Abstract ID</b>	<b>Presenter</b>	<b>Title</b>
S-001	QSP447	Georgi I. Kapitanov	Blinatumomab Trimer Formation - Insights From A Mechanistic PKPD Model On The Implications For Switching From Infusion To Subcutaneous Dosing Regimen In Acute Lymphoblastic Leukemia
S-002	PBPK378	Felix Stader	PBPK modelling relates subcutaneous bioavailability of mAbs to the saturation of FcRn-mediated recycling in dosing site draining lymph nodes
S-003	PMX276	Douglas Marsteller	Population Pharmacokinetic Analysis of Rocatinlimab, an Anti-OX40 Monoclonal Antibody
S-004	PMX277	Douglas Marsteller	Population Pharmacokinetic-Pharmacodynamic Analysis of Rocatinlimab, an Anti-OX40 Monoclonal Antibody
S-005	PMX421	Jennifer E. Hibma	Population pharmacokinetics of Elranatamab in patients with relapsed/refractory multiple myeloma from the Phase 1 first-in-patient study (MagnetisMM-1)
S-006	PMX424	Jennifer E. Hibma	Exposure-efficacy analysis for Elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) from the Phase 1 first-in-patient study (MagnetisMM-1)
S-007	PMX445	Jie Zhou	Target-Mediated Drug Disposition (TMDD) Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling of the Anti-FcRn Monoclonal Antibody Nipocalimab Administered to Healthy Subjects
S-008	PMX520	Anitha Saravanakumar	Population PKPD Modeling to Predict TAK-500 TMDD profiles in humans to enable first-in-human starting dose selection
S-009	QSP337	Xuyang Song	Dual Target-Mediated Drug Disposition (TMDD) Model to Guide the Selection of Starting Dose and Escalation in FTIH trials for MEDI5752, a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4
S-010	PMX340	Sihem Ait-Oudhia	Population Analyses of Pharmacokinetics, Safety, and Efficacy of Sotatercept in Patients with Pulmonary Arterial Hypertension

## ACoP13 Poster Session and Poster ID

<b>Monday, October 31</b>			
<b>Poster ID</b>	<b>Abstract ID</b>	<b>Presenter</b>	<b>Title</b>
M-001	QSP523	Alina Sofronova	An integrative mechanistic model of type 1 IFN-mediated inflammation in systemic lupus erythematosus
M-002	PBPK522	Zoe A Kane	Benznidazole pharmacokinetics in adults and children: Application of PBPK modeling to explore the impact of age on benznidazole pharmacokinetics.
M-003	QSP521	Fulya Akpinar Singh	Mechanistic target occupancy modeling for antibody format selection
M-004	PMX520	Anitha Saravanakumar	Population PKPD Modeling to Predict TAK-500 TMDD profiles in humans to enable first-in-human starting dose selection
M-005	Other519	Anitha Saravanakumar	Meta-analysis of clinical doses of oncology chimeric antigen receptor cell therapy and empirical preclinical to clinical dose translation
M-006	SFTL518	Ivan Borisov	Virtual Patients Parallel Simulations in a Hybrid Cloud Environment
M-007	PBPK517	Vivaswath S. Ayyar	Minimal physiologically-based pharmacokinetic (mPBPK) metamodeling of target engagement in psoriatic skin
M-008	PMX516	Naoki Kotani	Use of Open Clinical Trial Data Source, Project Data Sphere (PDS), for Tumor Growth Inhibition - Overall Survival (TGI-OS) Modeling of First-Line Metastatic Castrate Resistant Prostate Cancer (1L mCRPC)
M-009	Other515	Ron J Keizer	Adoption of model-informed precision dosing for antibiotic dosing in US hospitals
M-010	STPM514	Logan Brooks	Shap-Cov: Explainable machine learning for rapid Population Pharmacokinetic (PopPK) covariate identification
M-011	PMX513	Danna Chan	A Population Pharmacokinetic Model of Tolinapant in Subjects with Advanced Solid Tumors and Lymphomas
M-012	PMX511	Aram Ogenesian	Semi-Physiological PopPK Model Refined with Phase 3 Oral Fixed-Dose Combination Data of Cedazuridine with Decitabine in Myelodysplastic Syndrome Patients
M-013	PMX509	Aram Ogenesian	Extending a Semi-Physiological PopPK Model of the Oral Fixed-Dose Combination of Cedazuridine with Decitabine in Myelodysplastic Syndrome Patients to Characterize an Acute Myeloid Leukemia Patient Population
M-014	PMX508	Mutaz M. Jaber	Simultaneous Exposure Analysis of Total and Unbound R- and S-methadone Concentrations
M-015	PMX507	Zheng Lu	Bridging an Asian population receiving third line-or-later treatment of trastuzumab deruxtecan (T-DXd) to a Western population receiving second-line treatment in metastatic gastric cancer (GC) using a modeling and simulation framework

## ACoP13 Poster Session and Poster ID

M-016	PMX504	Zheng Lu	Pharmacometric analysis to support a higher recommended dose for trastuzumab deruxtecan (T-DXd) in the treatment of Western patients with metastatic gastric cancer (GC) versus breast cancer (BC)
M-017	STPM506	Mutaz M. Jaber	Evaluation of Recorded Time Deviations on Parameter Estimates in Nonlinear Mixed-effect Analyses
M-018	PMX505	Chee Ng	Model Informed Development of LRRK2 Inhibitor DNL201 in Parkinson's Disease: A Population Pharmacokinetics/Pharmacodynamics Approach for Dose Selection with a Sustained Release (SR) Formulation
M-019	QSP503	Christina Friedrich	Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology Model
M-020	PMX502	Jeffrey R Sachs	Effective Visualizations Reloaded – Visually Assess and Communicate Model Fit for Pmx Models with Covariates Using VACHETTE (an Extension of V2ACHER)
M-021	PMX501	Sara K. Quinney	Estimated neonatal gabapentin exposure through breast milk immediately postpartum using a population pharmacokinetic approach
M-022	PBPK500	Dwaipayan Mukherjee	Assessment of Drug-Drug Interactions of Navitoclax in Cancer Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations
M-023	MCS498	Varun Aggarwal	Survey of algorithms for building human activity recognition and verification framework
M-024	PMX497	Ming Zheng	Development of a Physiologically Based Pharmacokinetic (PBPK) Model for Quizartinib and Evaluation of Drug-Drug Interaction (DDI) Risk as an Inhibitor of UDP-Glucuronosyltransferase 1A1 (UGT1A1)
M-025	MCS496	Varun Aggarwal	Comparing Spatio-Temporal Reconstructions from Accelerometer and Gyroscope Data
M-026	PMX493	Masato Fukae	Landmark and longitudinal exposure-response analyses for multiple efficacy and safety endpoints to justify the clinical dose of valemestostat for adult T-cell leukemia/lymphoma
M-027	PMX492	Pavan Vaddady	Population Pharmacokinetics (PopPK) of Quizartinib and Its Active Metabolite AC886 in Patients With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
M-028	Other491	Varun Aggarwal	Evaluation of an open source gait feature extraction algorithm using an algorithmic literacy framework
M-029	QSP490	Hojjat Bazzazi	Parameters influencing target engagement of conditionally activated antibodies in tumor tissue: Investigations with a quantitative systems pharmacology model
M-030	PMX489	Masato Fukae	Simultaneous population pharmacokinetic analysis of total and unbound valemestostat in patients with non-Hodgkin lymphoma to quantify the effect of the binding protein, alpha 1-acid glycoprotein
M-031	QSP488	Rohit Rao	A QSP model of COVID-19 facilitates the clinical development of nirmatrelvir, a novel oral anti-viral for the treatment of COVID-19
M-032	Other487	Varun Aggarwal	Algorithmic literacy: a proposed framework for the assessment of algorithms as fit-for-purpose tools in clinical trials

## ACoP13 Poster Session and Poster ID

M-033	PMX392	Jace Nielsen	Exposure-Response Analysis of Fezolinetant in Women with Vasomotor Symptoms Associated with Menopause
M-034	PMX485	Pavan Vaddady	Concentration-QTcF Analysis of Quizartinib in Patients With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
M-035	PMX484	Allison Dunn	The Effect of Liver Dysfunction on the Pharmacokinetic Disposition of Belinostat and its Metabolites in Patients with Advanced Cancers
M-036	QSP483	Christina Friedrich	QSP Model of A $\beta$ Accumulation Predicts Different Treatment Effects at Different Stages of Alzheimer's Disease
M-037	QSP482	Silke Bergeler	The Impact of Tau Load and Genotypes on Cognitive Outcome in Amyloid Antibody Therapies. A Quantitative Systems Pharmacology Study
M-038	PBPK481	Jia Zhou	Application of a Physiologically-Based Pharmacokinetic (PBPK) Model to Predict the PK of Monoclonal Antibodies in Pediatric Subjects
M-039	PBPK480	Sanjana Parikh	Daunorubicin PBPK model in Lean and Overweight Children
M-040	QSP479	Mohammad Jafarnejad	Quantitative Systems Pharmacology Modeling of Enzyme Replacement Therapies for Mucopolysaccharidosis Type II Reveals Key Brain & CSF PK/PD Relationships
M-041	PMX478	Dawoon Jung	Pharmacokinetics of Plasma-derived Antithrombin III in Critically Ill Pediatric Patients Supported on Extracorporeal Membrane Oxygenation
M-042	STPM477	Erick Velasquez	External validation of tumor growth inhibition-overall survival model in non-small-cell lung cancer using pralsetinib RET-fusion positive solid tumor type data
M-043	QSP476	Lara Clemens	Proof-of-Concept that Variable Onset and Severity of T Cell-Mediated Drug-Induced Liver Injury is Reproduced in a Simulated Human Population
M-044	QSP475	Rohit Rao	Quantitative Systems Pharmacology & Virtual Patients: A Novel Approach for Improved Generation of Plausible Patients using Farthest Point Optimization
M-045	PMX474	Jenny-Hoa Nguyen	Population Pharmacokinetic (PopPK) Modeling of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Patients with Advanced Malignancies
M-046	PMX473	Shankar Lanke	Quantitative risk assessment enabled adavosertib monotherapy dose decision and mitigation of hematological toxicities and sepsis
M-047	PMX472	Tara Yang	Mechanistic PK-PD Modeling and Simulation of Reversal of the Effects of Potent Opioids by Naloxone Auto-Injector (NAI) 10 mg Across a Range of Different Opioids and Doses
M-048	PMX471	Anita Moein	An Item Response Theory Model with Bounded Integer Subcomponents to Describe the Mayo Clinic Subscores in Patients with Ulcerative Colitis
M-049	PMX470	Jasmine Hannah Hughes	One model to rule them all? Optimal model for model-informed precision dosing of vancomycin varies across healthcare providers

## ACoP13 Poster Session and Poster ID

M-050	PMX469	Wenlian Qiao	A computational model leveraging natural history study data to quantify drug efficacy in achondroplasia
M-051	PMX468	Yogesh Patel	Model-Informed Eteplirsen Dosing Regimen Extension Across Age Range for the DMD Population
M-052	PMX467	Timothy Rumbell	Constructing virtual cohorts that recreate data distributions using generative adversarial networks
M-053	STPM466	Matthew Wiens	A Model-Based Meta-Analysis for Treatment-Modified Disease Progression in Multiple Sclerosis
M-054	STPM465	Rashed Harun	Machine learning-based identification of risk factors of hyperglycemia following Ipatasertib treatment in a metastatic castration-resistant prostate cancer population
M-055	STPM464	Matthew Wiens	A Machine Learning and Statistical Meta-Analysis for Trial Simulations Predicting Transitions from Relapsing-Remitting to Secondary Progressive Multiple Sclerosis
M-056	PMX463	Florencio Serrano Castillo	Investigating the potential impact of dosing variability to facilitate use of Romiplostin self-administration in adult patients with ITP
M-057	QSP462	Polina Pchelintseva	Quantitative systems pharmacology model for neurofilament L dynamics in multiple sclerosis and under immunomodulatory therapies.
M-058	STPM461	Sarah Kim	Optimizing Use of Imaging Biomarkers in Clinical Trials for Duchenne Muscular Dystrophy: a Multivariate Model of a Fat Fraction Magnetic Resonance Biomarker and a Functional Endpoint
M-059	QSP459	Christina Battista	Representation of Fibrosis Stage within Mechanistic Model of Non-Alcoholic Fatty Liver Disease (NAFLD) / Non-Alcoholic Steatohepatitis (NASH) Aligns with Histologic Assessments
M-060	PMX458	Luke Fostvedt	PK/PD Modeling of Abrocitinib Exposure and Peak Pruritus NRS Score
M-061	PMX457	Nadia Noormohamed	Title: A Tale of Two Methods: A Comparison of Stepwise Covariate Modeling (SCM) and Manual Covariate Modeling
M-062	SFTL456	Matthew Riggs, Ph.D.	A suite of open-source tools to guide efficient pharmacometric analyses
M-063	QSP455	Vaibhav Maheshwari	Mechanistic In Silico Assessment of PROTAC Mediated On- and Off-Target Degradation of Cellular Proteins
M-064	QSP454	Chanchala Kaddi	Quantitative Systems Pharmacology model of Achondroplasia connecting FGFR3 hyperactivity to growth velocity: case study with vosoritide
M-065	SFTL453	Chee Meng Ng	Using Differential-algebraic Equation Solver to Develop Complex Mechanism based Competitive FcRn Receptor Binding Model in Population Data Analysis
M-066	QSP452	Limei Cheng	Mathematical Modeling of Renal Sodium, Potassium, and Glucose Dynamics in Diabetic and Non-diabetic Simulated Populations

## ACoP13 Poster Session and Poster ID

M-067	PMX451	Anitha Suram	Population PK model of Avapritinib in patients with Gastrointestinal Stromal Tumors and Advanced Systemic Mastocytosis
M-068	PMX450	Joseph Piscitelli	Extension to CP-1 Compartmental Models to Explore Unique Patterns in Cancer Patients Supporting Prediction of OATP1B1 Inhibition
M-069	QSP449	Georgi I. Kapitanov	Comparison Across Anti-PD-1 Antibodies - Insights From QSP-Based Meta-Analysis
M-070	STPM448	Alexander D. Becker	Lower Bound at Expiry (LoBE) Limits Provide Piercing Insights into Vaccine Manufacturing
M-071	QSP447	Georgi I. Kapitanov	Blinatumomab Trimer Formation - Insights From A Mechanistic PKPD Model On The Implications For Switching From Infusion To Subcutaneous Dosing Regimen In Acute Lymphoblastic Leukemia
M-072	Other446	Brooke Langevin	External Evaluation of Neonatal Opioid Withdrawal Syndrome Clinical Decision Support Systems
M-073	PMX445	Jie Zhou	Target-Mediated Drug Disposition (TMDD) Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling of the Anti-FcRn Monoclonal Antibody Nipocalimab Administered to Healthy Subjects
M-074	QSP444	Randolph J. Leiser	A Quantitative Systems Pharmacology Model of Osteogenesis Imperfecta
M-075	PMX443	Paul van den Berg	Population dose-Hgb modelling of daprodustat across five phase 3 studies in chronic kidney disease (CKD) patients with anemia
M-076	PMX442	Wendy Ankrom	Population pharmacokinetic analysis for pralsetinib in patients with RET-positive non-small-cell lung cancers (NSCLC) and RET-altered thyroid cancer
M-077	STPM441	Kristine Rosenberger	A Longitudinal Model-Based Meta-Analysis of absolute FVC in Idiopathic Pulmonary Fibrosis
M-078	PMX440	Paul van den Berg	Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population dose-hemoglobin model for daprodustat
M-079	QSP356	Tao Peng	Development of a Quantitative Systems Pharmacology Model for Atopic Dermatitis: From Biological Pathways to Virtual Patients and Clinical Endpoints
M-080	STPM355	Shuhui Li	Evaluating Novel Pilot Pharmacokinetic Bioequivalence Study for Inhalation Powder Drug Products Exhibiting Batch-to-Batch Deviation
M-081	PMX354	Shuhui Li	Exploration the Potential Impact of Batch-to-Batch Variability of Inhalation Powder Drug Products on Pharmacokinetic Bioequivalence Study Power
M-082	STPM353	Shuhui Li	Exploring the Relationship Between the In Vitro Properties and Pharmacokinetic Parameters of Advair Diskus

## ACoP13 Poster Session and Poster ID

<i>Tuesday, November 1</i>			
<b>Poster ID</b>	<b>Abstract ID</b>	<b>Presenter</b>	<b>Title</b>
T-001	MCS486	Kamrine E. Poels	A Mathematical Model of Tumor Evolution and ctDNA Release in Treated Lung Cancer Explores Tumor Response and Resistance to ALK Inhibitors
T-002	MCS499	Mahya Aghaee	Mathematical Optimization of Combination Therapy for Patients with Multiple Myeloma
T-003	MCS460	Mackenzie Dalton	The Response of Myosin to Membrane-Cortex Separation During Bleb Formation
T-004	MCS379	Freya Bachmann	Dealing with Parameter Uncertainty – a Sensitivity Analysis for Computing Optimal Drug Dosing with OptiDose
T-005	QSP512	Catherine Weathered	Microglia Behavior in Alzheimer’s Disease: An Agent-Based Model to Elucidate Microglial Spatiotemporal Response to Amyloid Beta
T-006	Other439	Aditi Shendre	The Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledgebase and Portal
T-007	STPM438	Garrett T Nieddu	Using sparse sampling schemes to design vaccine immunogenicity trials for determining durability of immunogenicity
T-008	STPM437	Mario Nagase	An Application of Neural-ODE to Population Pharmacokinetic Modeling
T-009	PMX436	Sharvari Bhagwat	PK/PD Characterization of INBRX-101, a Novel, Recombinant Alpha-1 Antitrypsin Fusion Protein, in Patients With Alpha-1 Antitrypsin Deficiency
T-010	PMX435	Chih-Wei Lin	A Platform Model for Multiple Time-To-Event Endpoints in Oncology Clinical Trials
T-011	PMX434	Kelly M. Mahar	Population pharmacokinetics of daprodustat across five phase 2b/3 studies in chronic kidney disease (CKD) patients with anemia
T-012	QSP433	Iñaki F. Trocóniz	A mechanism-based pharmacokinetic/pharmacodynamic model for a novel oncolytic virus in monotherapy or combination with pembrolizumab.
T-013	QSP432	Cole Zmurchok	Clinical variance in CAR-T pharmacology deconvoluted using a mathematical model of T cell regulatory control
T-014	PBPK431	Lais Da Silva	Development and Validation of a Whole-body PBPK Model of Drospirenone for Drug-drug Interaction Studies
T-015	STPM430	Jian Zhou	Model-Based Meta-Analysis for Major Adverse Cardiovascular Events in Autoimmune Diseases Clinical trials – to Predict the Real-World Data
T-016	PMX429	Rena Byrne	A Population Pharmacokinetic Model and Exposure-Response Model of Repeated Time Event (RTTE) to Justify a Dose Increase in Patients with Sickle Cell Disease
T-017	PBPK428	Leyanis Rodriguez Vera	Applying Physiologically-Based Pharmacokinetic (PBPK) Modeling to Assess Complex Metabolic-Mediated Drug-Drug Interactions (DDIs).

## ACoP13 Poster Session and Poster ID

T-018	QSP427	Madhav Channavazzala	Development of a mechanistic mPBPK/QSP Antibody drug conjugates (ADC) platform model with applications across preclinical, translational and clinical stages of drug development.
T-019	PBPK426	Shintaro Nakayama	Development of a Physiologically Based Pharmacokinetic (PBPK) Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
T-020	SFTL425	James Craig	Intersection of software development and Certara scientific innovation: a collaborative approach to developing professional open source PMx R packages
T-021	PMX424	Sibo Jiang	Exposure-efficacy analysis for Elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) from the Phase 1 ?rst-in-patient study (MagnetisMM-1)
T-022	STPM423	James A. Rogers	Analysis Planning and Interpretation Using Causal Directed Acyclic Graphs: A Case Study in Oncology
T-023	STPM422	Cameron McBride	Quantifying Uncertainty of Systems Model Predictions to Uncertainty in Fixed Parameters
T-024	PMX421	Jennifer E. Hibma	Population pharmacokinetics of Elranatamab in patients with relapsed/refractory multiple myeloma from the Phase 1 ?rst-in-patient study (MagnetisMM-1)
T-025	PMX420	Mario Nagase	Population Pharmacokinetic Analysis of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients with a KRASG12C Mutation from Phase 1 and Phase 2 Studies
T-026	STPM418	Xinyi Pei	Population PK Analysis of Somatrogen Using a Bayesian Approach with Informative Priors
T-027	PBPK417	Xiaonan Li	Liver-to-Plasma Partition Coefficients and In Silico Calculation Methods Differ with Hepatic Clearance Models
T-028	PMX416	Xiaofei Zhou	Population Pharmacokinetics and Exposure-Efficacy Analyses of Pevonedistat, a NEDD8-Activating-Enzyme Inhibitor, in Patients with Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia
T-029	PMX415	Alexander Kulesza	A disease drug trial model for multiple applications in the development of respiratory infection prophylaxis
T-030	STPM414	Sheetal Panday	Predicting the Incidence Proportion of Drug-Induced Serotonin Syndrome-Associated Tremors Using a Model-based Meta-Analysis
T-031	PBPK413	Marian Klose	The Impact of UGT2B7 and CYP2D6 Gene-Drug- and CYP-mediated Drug-Drug-Interactions on Oxycodone and Oxymorphone Pharmacokinetics using PBPK Modelling
T-032	PMX412	Ahmed M Salem	A Full Bayesian Approach for Population Pharmacokinetic/Pharmacodynamic Modeling of Unfractionated Heparin in Pediatrics
T-033	QSP411	Alexander Kulesza	A quantitative systems pharmacology model for atopic dermatitis clinical trial design and biomarker identification: oral immunomodulator on top of topical steroids after induction period
T-034	STPM410	Lindsay Clegg	Population Pharmacokinetic Simulation-based Design of a Three Drug Bioequivalence Study for the Breztri Aerosphere Next-Generation Propellant Program



## ACoP13 Poster Session and Poster ID

T-035	STPM409	Lucie Fayette	Pharmacometrics Enhanced Bayesian Borrowing
T-036	STPM408	Xinrui Zhang	Bayesian Horseshoe prior for covariate selection in Exposure-Response analysis
T-037	PMX407	Claude Magnard	Pharmacokinetic Modeling of Fentanyl Citrate and Norfentanyl in Calves Using a Nonlinear Mixed-Effects Approach
T-038	STPM406	Peter Bonate	Investigation of potential applications of machine learning in covariate screening.
T-039	STPM405	Michael Pauley	Quantifying the impact of a high burden chronic disease on a clinical trial using clinical trial simulation tools
T-040	QSP404	Tatiana Karelina	Quantitative systems pharmacology modeling of immune response role in Parkinson's disease
T-041	SFTL403	Elisabeth Roesch	Pumas-QSP: A high-performance and easy-to-use modeling tool for Advanced Pharmaceutical Sciences
T-042	PMX402	Salim Bouchene	Elacestrant Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Elacestrant Dose Recommendations in Metastatic Breast Cancer (mBC) patients
T-043	PBPK291	Kai Liu	Physiologically Based Pharmacokinetic (PBPK) Model Of Sparsentan To Evaluate Drug-Drug Interaction Potential
T-044	STPM400	Douglas Marsteller	Markovian Chain Exposure-Response Analysis of Istradefylline (KW-6002) Assessed Using Daily Diary
T-045	PMX399	Yali Liang	Generalized Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling and Simulation of Myelosuppression Following Combination Therapy of Lurbinectedin with Talazoparib
T-046	PMX398	Megan Melch	Population Plasma Pharmacokinetic Analysis of Vutrisiran in Healthy Subjects and hATTR Amyloidosis Patients with Polyneuropathy
T-047	PMX397	Azar Shahraz	Tumor Size Modeling Enables Selection of the Phase 3 Dose and Schedule for Savolitinib in Combination with Osimertinib
T-048	PMX396	Samira Merali	Modeling and simulation to investigate dose titration regimen for mavacamten in adults with obstructive hypertrophic cardiomyopathy (HCM)
T-049	PMX394	Amit Roy	Population pharmacokinetics of mavacamten in adults with obstructive hypertrophic cardiomyopathy (HCM)
T-050	PMX393	Monika Twarogowska	A method to correct VPC bias due to non-random dropout via censored data addition using the MonolixSuite
T-051	QSP391	Veronica Musatova	Methodological aspects of rate law derivation of cell dynamics processes: focus on QSP model development
T-052	PMX390	Franco Mihaljevic	Development of a level A in vitro/in vivo correlation (IVIVC) using applications of the MonolixSuite
T-053	QSP389	Pauline Traynard	Comparison of a typical PK/PD model versus a mechanistic QSP model to predict the Phase II of a PSCK9 inhibitor, using MonolixSuite

## ACoP13 Poster Session and Poster ID

T-054	QSP388	Veronica Musatova	Estimation of I <sub>max</sub> and IC <sub>50</sub> for PD1-PDL1 inhibition of T cell proliferation
T-055	SFTL387	Jonathan Chauvin	RsPKanalix: an open-source package for MonolixSuite data formatting and reporting in R
T-056	PMX386	Samira Merali	Exposure-response modeling of mavacamten in adults with hypertrophic cardiomyopathy (HCM)
T-057	PBPK384	Denise Türk	PBPK Models for OCT2 and MATE Interaction Predictions: A Drug-Biomarker Interaction Network of Creatinine, N1-Methylnicotinamide, Trimethoprim, Pyrimethamine and Cimetidine
T-058	PBPK383	Sandra Granana Castillo	Evaluation of drug-drug interaction between rilpivirine and daily/weekly rifapentine through physiologically based pharmacokinetic (PBPK) modelling
T-059	QSP382	Denison Kuruvilla	Predicting Anti-drug Antibody Incidence with a Quantitative Systems Pharmacology Immunogenicity Platform: A Case Study for Etolizumab in Patients with Moderate to Severe Ulcerative Colitis
T-060	PMX381	Denison Kuruvilla	Prediction Of Overall Survival In Melanoma Patients Following Atezolizumab Treatment: A Tumor Growth Inhibition–Overall Survival Modeling Framework
T-061	QSP380	Stepan Lerner	The QSP model of microglia role in tau pathology and neurodegeneration
T-062	PBPK378	Felix Stader	PBPK modelling relates subcutaneous bioavailability of mAbs to the saturation of FcRn-mediated recycling in dosing site draining lymph nodes
T-063	STPM377	Izumi Hamada	Characterization of Tumor-Growth-Dynamic (TGD) in first-line metastatic non-small cell lung cancer (1L mNSCLC) with Nivolumab and ipilimumab (NIVO+IPI) with or without chemotherapy: Analysis of Asian and Non-Asian Populations
T-064	STPM376	Federico Reali	A hybrid minimal PBPK and machine learning approach to predict drug penetration in tuberculosis lesions.
T-065	QSP375	Oleg Demin	Pharmacokinetics modeling and optimal dose prediction for a bispecific antibody against CD40 and PD1
T-066	PBPK374	Abdul Naveed Shaik	A Physiologically Based Pharmacokinetic Model of Long-Acting Lenacapavir
T-067	PMX372	Seung Chan Choi	Simulation Study to Explore Optimal Sampling Time for Therapeutic Drug Monitoring of Voriconazole
T-068	PMX371	Hyeong-Seok Lim	Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Prasugrel in Healthy Male Volunteers
T-069	PMX370	Hongtao Yu	Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes and NASH
T-070	PMX369	Joseph J. Raybon	Disease Progression Modeling of MDS-UPDRS Composite Score to Inform Clinical Trial Design in Patients with Parkinson's Disease

## ACoP13 Poster Session and Poster ID

T-071	PMX368	Brian Jermain	Development of Adaptive Dose Simulations Using R and mrgsolve to Improve Tolerability While Maximizing Dose Intensity in Oncology
T-072	QSP367	Ronny Straube	Effect of Breathing and Internalization on Antibody-Receptor Binding: What we can learn from the shape of the Binding Curve
T-073	PMX366	Fernando Carreño	Predictive Performance of Belantamab Mafodotin Population Pharmacokinetics Model in Earlier-Line Multiple Myeloma Patients
T-074	PMX365	Kashyap Patel	Impact of Exposure Metric on Binary Endpoints in Exposure-Response Analyses
T-075	STPM363	Kosalaram Goteti	Application of Model-Based Meta-Analysis to Set Benchmarks for New Treatments of Systemic Lupus Erythematosus
T-076	PMX362	Conor J. O'Hanlon	Consistent methods for Fat Free Mass, Creatinine Production Rate, Creatinine Clearance and Glomerular Filtration Rate for description of Renal Function in neonates to adults
T-077	STPM361	Kai Wang	Estimation of Time to Progression and Post Progression Survival through Joint Modeling of Overall Survival and Progression-free Survival following Anti-PD1 Treatments across Oncology Indications
T-078	PMX360	Fan Wu	Population pharmacokinetic modeling for CC-99282, a novel cereblon E3 ligase modulator (CELMoD) agent, in patients with relapsed or refractory non-Hodgkin lymphoma
T-079	PMX359	Nicole Rivera Rosario	Exposure-Response and Time-Course Analysis of Istradefylline (KW-6002) UPDRS II/III Using Graded Item Response Theory Approach
T-080	PMX358	Nicole Hobbs	Biophysical simulation approach for dose escalation in Phase I clinical trials
T-081	PMX357	Shihao Hu	Pharmacokinetics of the Engineered Fc-IL-15 Proteolytically Activated Cytokine Prodrug ASKG315
T-082	PBPK510	Parsshava Mehta	Application of interspecies PBPK modeling to characterize BBB permeability using levetiracetam and acetaminophen as model drug

## ACoP13 Poster Session and Poster ID

<b>Wednesday, November 2</b>			
<b>Poster ID</b>	<b>Abstract ID</b>	<b>Presenter</b>	<b>Title</b>
W-001	PMX352	Huili Chen	Integrating Operational Model of Agonist in Model-Based Meta-Analysis for Assessing Inhibition of Ovulation Rate by Different Progestins
W-002	PMX351	Shuhui Li	Population Pharmacokinetic Modeling for Fluticasone Propionate and Salmeterol Xinafoate Inhalation Powder in a Bioequivalence Study
W-003	PBPK350	Gregory Z. Ferl	Virtual population and non-linear mixed-effects approaches to mechanistic hypothesis exploration of a physiologically-based ocular model to support preclinical and clinical drug development
W-004	STPM349	Matthew Putnins	Powering And Designing Clinical Trials Using Exposure Response Modeling
W-005	PMX348	Jia Zhou	A Mechanism-based PK/PD Model to Predict Pharmacodynamics-Mediated Drug-Drug Interaction Propensity for Anti-FcRn Antibodies
W-006	PMX347	Po-Wei Chen	Comparison of Item Response Theory Modeling Frameworks between Two Patient-Reported Outcomes (PROs) in Migraine Prevention Drug Development
W-007	PBPK346	Yoo-Seong Jeong	Determination of the Number of Tissue Groups with Kinetically Distinct Transit Times in Whole-body Physiologically-Based Pharmacokinetic (PBPK) Models: Theoretical Consideration of Bottom-Up Approach to Lumping Tissues in Whole-body PBPK
W-008	PBPK345	Yannick Hoffert	Leveraging Physiologically Based Pharmacokinetic (PBPK) Modeling to Explore the Role of OCT1 on Tramadol and its Active Metabolite Exposure in Healthy Adults and Children
W-009	PBPK344	Chandrali Bhattacharya	Physiologically-Based Pharmacokinetic (PBPK) Model Development and Validation of AZD4831 and Application to Predict Drug-Drug Interaction with CYP3A4 Substrate
W-010	MCS343	Gengbo Liu	Deep-NCA: a Deep Learning methodology for performing Non-Compartmental Analysis
W-011	PMX342	Tina Checchio	An Evaluation of the Methodology Employed during Generation of Simulation Datasets during Pharmacometric Modeling.
W-012	PMX341	Jenny Zheng	Two Population Pharmacokinetic Analyses of Somatrogen in Patients with Growth Hormone Deficiency
W-013	PMX340	Sihem Ait-Oudhia	Population Analyses of Pharmacokinetics, Safety, and Efficacy of Sotatercept in Patients with Pulmonary Arterial Hypertension
W-014	SFTL339	Erik Hahn	An Oncology Dashboard for real-time analysis of early phase clinical PK/PD data using ROracle and R-Shiny
W-015	QSP338	Ishaan Dave	A semi-mechanistic model of the effect of renal function on BNP and NT-proBNP biomarkers

## ACoP13 Poster Session and Poster ID

W-016	QSP337	Xuyang Song	Dual Target-Mediated Drug Disposition (TMDD) Model to Guide the Selection of Starting Dose and Escalation in FTIH trials for MEDI5752, a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4
W-017	QSP336	Hongtao Yu	Mathematical modeling of the physiology of endothelin-1 and its receptors A and B
W-018	SFTL335	Donald Irby	ERMod: A Semi-Automated Exposure-Response (E-R) Analysis and Reporting Tool to Support Decision Making While Increasing Time and Cost Savings in Drug Development
W-019	QSP334	Theodore R. Rieger	An Integrated QSP Model of Lipoproteins with Liver Metabolism for Non-Alcoholic Fatty Liver Disease and Hyperlipidemia
W-020	PMX333	Tianjing Ren	Pharmacodynamic Model of Slow Reversible Binding and its Applications in PK/PD modeling: Review and Tutorial
W-021	QSP332	Liam V Brown	Applying Population Mechanistic Modelling to Understand Population Level CAR-T Dynamics in Lymphoma Patients
W-022	QSP331	Sanchita Basu	Mechanistic Modeling of Heart Failure with Preserved Ejection Fraction: Understanding the Pathophysiology
W-023	QSP330	Rolien Bosch	Linking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity
W-024	QSP329	Gregory Z. Ferl	Mechanistic model for the impact of valency on cellular uptake and residualization of bispecific antibodies
W-025	STPM328	Varun Aggarwal	Multivariate Joint Models to Predict Clinically Meaningful Decline in Duchenne Muscular Dystrophy as measured by NSAA Using Timed Function Test Trajectories.
W-026	QSP327	Blerta Shtylla	A novel virtual population simulation workflow for a QSP model of solid tumor targeted therapy
W-027	QSP326	Tyler Cassidy	QSP Modelling of MAPK Pathway in BRAF Mutant Melanoma Cells
W-028	PMX325	Thanh Bach	Population Pharmacokinetic Model of Agalsidase-Migalastat Interaction: A Novel Mechanistic Model of Drug-Drug Interaction Between a Therapeutic Protein and a Small Molecule
W-029	STPM324	Rahul Kumar Goyal	Unsupervised Hierarchical Clustering Analysis for the Characterization of Sequence of Pancytopenia in Male and Female Non-human Primates Post Total Body Irradiation
W-030	STPM323	Rahul Kumar Goyal	Application of Machine Learning Analysis to Inform Medical Countermeasure Development – A Case Study Using Random Forest Ensemble to Identify Predictive Biomarkers of Mortality for Hematopoietic Acute Radiation Syndrome and Confirmation of Benefit with Leukine® Across Myeloid Lineages
W-031	STPM322	Nakyo Heo	Strategies for the selection of informed PK sampling timepoints in late phase trials
W-032	QSP321	Kumpal Madrasi	Prediction of a MABEL-based Starting Dose and Biologically Active Doses of a MSLN x CD137 bispecific conditional immune agonist(M9657) using a mechanistic QSP model

## ACoP13 Poster Session and Poster ID

W-033	PMX320	Megan Melch	Population Plasma Pharmacokinetic Analysis of Lumasiran in Pediatric and Adult Primary Hyperoxaluria Type 1 Patients
W-034	QSP319	Jin Niu	Development of A Platform Quantitative Systems Pharmacology (QSP) Model to Predict the Clinical Responses of T-cell Redirecting Bispecific Antibodies in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
W-035	PMX318	Hardik Chandasana	Population Pharmacokinetic Analyses of DOVATO (Dolutegravir/Lamivudine) Fixed-Dose Combination in HIV-Infected Patients
W-036	STPM317	Luke Kosinski	A nonparametric sample size calculator in the presence of missing values for a kidney allograft composite biomarker
W-037	PBPK316	Annie Lumen	Physiologically Based Pharmacokinetic Modeling to Predict Human Ocular Pharmacokinetics and Ocular Toxicity of Systemically Administered Anticancer Therapeutic Proteins for Dosing Regimen Optimization in Oncology Patients
W-038	PBPK315	Salim Bouchene	Development of a Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model to Predict MEN1703 Tissue Distribution in Humans
W-039	QSP314	Erfan Maddah	Integration of a potassium-aldosterone homeostasis model into a cardiorenal QSP model
W-040	PMX313	Tong Lu	Polatuzumab Vedotin Population Pharmacokinetics (popPK) and Exposure-Response (ER) Analyses From the POLARIX Study in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
W-041	PMX312	Lihong Du	A Bayesian Population Pharmacokinetic Model for Imipenem and Relebactam to Support Selection of Optimal Dosing Regimens for Children of Less Than 2 Years of Age
W-042	PMX311	Minhyung Lee	Pharmacokinetic and Pharmacodynamic Modeling Analysis of Zectivimod in Healthy Volunteers
W-043	QSP310	Jaehee Shim	Predicting disease activity scores in Irritable Bowel Disease (IBD) by connecting simulated tissue biomarkers of a virtual population (VPop) to clinical biomarkers and outcomes using a novel algorithm
W-044	PBPK309	Xinwen Zhang	Physiologically Based Pharmacokinetic Modeling to Predict Adult and Pediatric Pharmacokinetics of Bispecific T Cell Engager Antibodies for Solid Tumor Indications
W-045	PMX308	Yasong Lu	A Comprehensive, Quantitative Evaluation of the Safety Profile of Dato-DXd, a TROP2-Directed Antibody-Drug Conjugate, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
W-046	PMX307	Hyun Chul Kim	Population Pharmacokinetic Analysis of HSG4112, a Synthetic Glabridin Derivative, in Healthy Subjects
W-047	PMX306	Yanke Yu	Pharmacodynamic Modeling of Regenerating Islet Protein 3A (Reg3A) in Subjects Treated With Efmarodocokin alfa (IL-22Fc)
W-048	PMX305	Yanke Yu	Population Pharmacokinetics (PK) of Efmarodocokin alfa (IL-22Fc)

## ACoP13 Poster Session and Poster ID

W-049	PMX304	Husain Attarwala	Immunostimulatory/Immunodynamic Model of an mRNA-Based Vaccine Against Cytomegalovirus Infection to Guide Vaccine Dose Selection
W-050	PMX303	Elise Oh	PKPD Modeling to Characterize Placebo and Treatment Effect of Omalizumab for Chronic Spontaneous Urticaria (CSU)
W-051	QSP302	Jessica C. Leete	Virtual population simulations of an anti-PD-(L)1 QSP model for first-in-human dose prediction
W-052	STPM301	Arya Pourzanjani	A Flexible Joint Model of PK/PD and Progression-Free Survival for Assessing Efficacy in Early Oncology Trials
W-053	QSP300	Katy Norman	Quantitative Systems Pharmacology (QSP) Model Linking the Action of the CXCR4-Antagonist Mozobil to Both Immune Cell Mobilization from Bone Marrow and Immune Cell Infiltration in Colorectal Cancer (CRC)
W-054	SFTL298	Heajin Jun	Automation Tool Development for Phase 1 Pharmacokinetic Data
W-055	QSP297	Weize Huang	A quantitative systems pharmacology (QSP) model to predict kinetics of TCR-engineered T cells in solid tumors
W-056	QSP296	Tomoki Yoneyama	A translational quantitative systems pharmacology modeling framework for exon skipping oligonucleotide therapies for Duchenne muscular dystrophy
W-057	PMX295	Soyoung Lee	Population pharmacokinetic-pharmacodynamic model of long-acting granulocyte colony-stimulating factor, tripegfilgrastim, to the neutrophil response in healthy adults and pediatric patients after chemotherapy
W-058	QSP294	Joe Bender	A Multiscale Quantitative Systems Pharmacology Model of Pulmonary Arterial Hypertension
W-059	PMX293	Krina Mehta	Burosumab Treatment-Induced Increases in Serum Phosphate Provide Improvements in Patient Reported Outcomes in Adults with X-Linked Hypophosphatemia as Assessed with Graded Item Response Analysis
W-060	PMX292	Congyu Zhang	Across-species meta-analysis of betamethasone pharmacokinetics comparing compartmental and minimal PBPK models
W-061	QSP290	Jeffrey D Kearns	Preclinical pharmacokinetics and target occupancy of JDQ443, a covalent inhibitor targeting KRAS G12C
W-062	PMX289	Jae Eun Ahn	Population PK and PK/PD Analysis of Vupanorsen using Phase 1 and 2 Studies
W-063	STPM288	Jae Eun Ahn	Model-Based Meta-Analysis of Lipid Endpoints in Patients with Hypertriglyceridemia
W-064	Other287	Eric Haseltine	Automated, Reproducible Computing for Pharmacometric Modeling Using the Open-Source Tool GNU Make
W-065	PMX286	Alex Yu	Demonstrating Bioequivalence of Apalutamide when Administered in Applesauce versus Whole Tablets Using Clinical Trial Simulation
W-066	PMX285	Ka Lai Yee	Item Response Theory Modeling for Detection of Cognitive Symptomatic Treatment Effects in Alzheimer's Disease

## ACoP13 Poster Session and Poster ID

W-067	QSP284	Tariq Abdulla	Incorporating User-Defined Hemodynamic Feedback in PBPK-PD Models
W-068	PMX283	Jongtae Lee	Population Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of Lumasiran Effect on Spot Urinary Oxalate:Creatinine Ratio (UOx:Cr) in Pediatric (Infants to 18 Years of Age) and Adult Primary Hyperoxaluria Type 1 Patients
W-069	PMX282	Jongtae Lee	Population Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of Lumasiran in Primary Hyperoxaluria Type I Patients = 6 Years of Age
W-070	PMX281	Satyawan B. Jadhav	Population Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of Vutrisiran in Healthy Subjects and hATTR Amyloidosis Patients with Polyneuropathy
W-071	PMX280	Shuang Liang	Population pharmacokinetic and pharmacodynamic modelling of Dato-DXd in patients with advanced or metastatic NSCLC
W-072	PMX277	Hiroki Okada	Population Pharmacokinetic-Pharmacodynamic Analysis of Rocatinlimab, an Anti-OX40 Monoclonal Antibody
W-073	PMX276	Hiroki Okada	Population Pharmacokinetic Analysis of Rocatinlimab, an Anti-OX40 Monoclonal Antibody
W-074	PBPK275	Ahmed Elmokadem	Bayesian PBPK Modeling using R/Stan/Torsten and Julia/SciML/Turing.jl
W-075	PMX274	Shankar Lanke	Update of population pharmacokinetics and exposure-response of olaparib incorporating data from OlympiA patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer
W-076	Other272	Chihiro Hasegawa	Exploring Improper Lumping as a Diagnostic Tool When Reducing the Scale of High-Dimensional Models Using Proper Lumping
W-077	PBPK271	Michael J Dolton	Integrating Dynamic in vitro Systems and Mechanistic Absorption Modelling: Case Study of Pralsetinib
W-078	STPM270	Jim H. Hughes	Model-Based Meta-Analysis of Weight Loss in Type 2 Diabetic and Obese Populations
W-079	PMX269	Phyllis Chan	Model estimates of baseline prognostic and treatment impacts on tumor growth inhibition (TGI) in non-small cell lung cancer (NSCLC)
W-080	PMX267	Phyllis Chan	A tumor growth inhibition-overall survival (TGI-OS) model in unresectable hepatocellular carcinoma (HCC)
W-081	PBPK266	Lu Gaohua	Interplay of permeability, metabolism, transporters, and dosing in determining the dynamics of tissue/plasma partition coefficient ( $K_p$ ) and volume of distribution ( $V_d$ ) – a theoretical investigation using permeability-limited physiologically-based pharmacokinetic (PBPK) modeling
W-082	MCS401	John C. Panetta	Advancing Optimal Control in Pharmacometrics: Mathematical and Computational Sciences SIG Optimal Control Working Group